// App-Quantinova.ai

EP1049 : CILTACABTAGENE AUTOLEUCEL VERSUS SELINEXOR + DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH ≥3 LINES OF PRIOR THERAPY: A MATCHING ADJUSTED INDIRECT COMPARISON

Researchers

Presenter

  • Tom Martin

Principal Investigators

  • Kwee Yong

  • Jordan M. Schecter

  • Martin Vogel

  • Carolyn C. Jackson

  • William Deraedt

  • Hong Tian

  • Tzu-min Yeh

  • Arnob Banerjee

  • Marlene J. Carrasco-Alfonso

  • Xiaoling Wu

  • Tonia Nesheiwat

  • Suzy Van Sanden

  • Joris Diels

  • Satish Valluri

  • Saad Z. Usmani

  • Jesus G. Berdeja

  • Sundar Jagannath

  • Katja Weisel

Medical Centers

  • Janssen R&amp

  • Legend Biotech USA,Piscataway, NJ,United States

  • D,Beerse,Belgium

  • Sarah Cannon Research Institute, Nashville,United States

  • Mount Sinai Medical Center, New York, United States

  • Janssen Global Services, Raritan, NJ, United States

  • Kings College London, London, United Kingdom

  • Levine Cancer Institute/Atrium Health,Charlotte,Verenigde Staten

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • D,Raritan,United States

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, La Verne, CA

  • D,Spring House,United States

Locations

  • United States

  • Belgium

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Selinexor

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03548207

  • NCT02336815

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved